Veru (VERU) Total Non-Current Liabilities (2016 - 2026)
Veru (VERU) posted quarterly Total Non-Current Liabilities of $7.5 million for Q1 2026, down 9.24% year-over-year from $8.3 million in Q1 2025, and down 19.74% quarter-over-quarter from $9.3 million in Q4 2025.
Veru (VERU) Total Non-Current Liabilities (2016 - 2026) Analysis & Trends
Veru (VERU) has reported Total Non-Current Liabilities for 11 consecutive years, with $7.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Non-Current Liabilities fell 9.24% year-over-year to $7.5 million; the TTM figure through Mar 2026 stood at $7.5 million (down 9.24% YoY), while the FY2025 annual figure was $10.1 million, down 57.09% from the prior year.
- Total Non-Current Liabilities retreated to $7.5 million in Q1 2026 per VERU's latest filing, from $9.3 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $52.5 million in Q3 2022 and bottomed at $7.5 million in Q1 2026.
- Historically, Total Non-Current Liabilities has averaged $26.5 million across 5 years, with a median of $23.0 million in 2024.
- Annual changes were most pronounced in 2022 — Total Non-Current Liabilities jumped 115.6% — and 2025, when it sank 61.77%.
- Veru's Total Non-Current Liabilities stood at $52.1 million in 2022, then slumped by 41.77% to $30.3 million in 2023, then slumped by 69.9% to $9.1 million in 2024, then rose by 2.38% to $9.3 million in 2025, then fell by 19.74% to $7.5 million in 2026.
- Business Quant data shows VERU's Total Non-Current Liabilities at $7.5 million in Q1 2026, $9.3 million in Q4 2025, and $10.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.32 Bn |
| 10 | Veru | 60.85 Mn | 35.06 Mn | - | 8.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.06 Mn |
| Mar 31, 2026 | 7.50 Mn |
| Dec 31, 2025 | 9.34 Mn |
| Sep 30, 2025 | 10.14 Mn |
| Jun 30, 2025 | 9.18 Mn |
| Mar 31, 2025 | 8.26 Mn |
| Dec 31, 2024 | 9.12 Mn |
| Sep 30, 2024 | 23.64 Mn |
| Jun 30, 2024 | 22.27 Mn |
| Mar 31, 2024 | 21.60 Mn |
| Sep 30, 2023 | 30.31 Mn |
| Jun 30, 2023 | 39.52 Mn |
| Mar 31, 2023 | 48.49 Mn |
| Dec 31, 2022 | 52.06 Mn |
| Sep 30, 2022 | 52.54 Mn |
| Jun 30, 2022 | 43.69 Mn |
| Mar 31, 2022 | 36.81 Mn |
| Dec 31, 2021 | 24.15 Mn |
| Sep 30, 2021 | 25.84 Mn |
| Jun 30, 2021 | 25.09 Mn |